|Publication Type||Journal Article|
|Year of Publication||2019|
|Authors||Nissim, S, Leshchiner, I, Mancias, JD, Greenblatt, MB, Maertens, O, Cassa, CA, Rosenfeld, JA, Cox, AG, Hedgepeth, J, Wucherpfennig, JI, Kim, AJ, Henderson, JE, Gonyo, P, Brandt, A, Lorimer, E, Unger, B, Prokop, JW, Heidel, JR, Wang, X-X, Ukaegbu, CI, Jennings, BC, Paulo, JA, Gableske, S, Fierke, CA, Getz, G, Sunyaev, SR, J Harper, W, Cichowski, K, Kimmelman, AC, Houvras, Y, Syngal, S, Williams, C, Goessling, W|
|Date Published||2019 Sep|
Pancreatic ductal adenocarcinoma is an aggressive cancer with limited treatment options. Approximately 10% of cases exhibit familial predisposition, but causative genes are not known in most families. We perform whole-genome sequence analysis in a family with multiple cases of pancreatic ductal adenocarcinoma and identify a germline truncating mutation in the member of the RAS oncogene family-like 3 (RABL3) gene. Heterozygous rabl3 mutant zebrafish show increased susceptibility to cancer formation. Transcriptomic and mass spectrometry approaches implicate RABL3 in RAS pathway regulation and identify an interaction with RAP1GDS1 (SmgGDS), a chaperone regulating prenylation of RAS GTPases. Indeed, the truncated mutant RABL3 protein accelerates KRAS prenylation and requires RAS proteins to promote cell proliferation. Finally, evidence in patient cohorts with developmental disorders implicates germline RABL3 mutations in RASopathy syndromes. Our studies identify RABL3 mutations as a target for genetic testing in cancer families and uncover a mechanism for dysregulated RAS activity in development and cancer.
|Alternate Journal||Nat. Genet.|
|Grant List||K08 DK105326 / DK / NIDDK NIH HHS / United States|